Patrik Nasr

List of Publications by Year in descending order

33 papers	5,448 citations	361296 20 h-index	414303 32 g-index
34 all docs	34 docs citations	34 times ranked	5716 citing authors

#	Article	IF	Citations
1	Fibrosis stage is the strongest predictor for diseaseâ€specific mortality in NAFLD after up to 33 years of followâ€up. Hepatology, 2015, 61, 1547-1554.	3.6	1,683
2	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and metaâ€analysis. Hepatology, 2017, 65, 1557-1565.	3.6	1,294
3	Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of Hepatology, 2017, 67, 1265-1273.	1.8	730
4	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology, 2020, 158, 1611-1625.e12.	0.6	575
5	Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A longâ€term followâ€up study. Hepatology Communications, 2018, 2, 48-57.	2.0	200
6	Natural History of NAFLD/NASH. Current Hepatology Reports, 2017, 16, 391-397.	0.4	102
7	Natural history of nonalcoholic fatty liver disease: A prospective followâ€up study with serial biopsies. Hepatology Communications, 2018, 2, 199-210.	2.0	102
8	Cardiovascular risk factors in nonâ€alcoholic fatty liver disease. Liver International, 2019, 39, 197-204.	1.9	75
9	Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1148-1156.e4.	2.4	71
10	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemporary Clinical Trials, 2020, 98, 106175.	0.8	71
11	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. Journal of Hepatology, 2022, 76, 1013-1020.	1.8	66
12	Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2017, 52, 159-165.	0.6	60
13	Elevated serum ferritin is associated with increased mortality in nonâ€alcoholic fatty liver disease after 16 years of followâ€up. Liver International, 2016, 36, 1688-1695.	1.9	54
14	Using a 3% Proton Density Fat Fraction as a Cut-Off Value Increases Sensitivity of Detection of Hepatic Steatosis, Based on Results From Histopathology Analysis. Gastroenterology, 2017, 153, 53-55.e7.	0.6	51
15	Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus. Metabolism: Clinical and Experimental, 2021, 115, 154439.	1.5	41
16	Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2020, 111, 154183.	1.5	39
17	SAF score and mortality in NAFLD after up to 41 years of follow-up. Scandinavian Journal of Gastroenterology, 2017, 52, 87-91.	0.6	32
18	The amount of liver fat predicts mortality and development of type 2 diabetes in nonâ€alcoholic fatty liver disease. Liver International, 2020, 40, 1069-1078.	1.9	31

#	Article	IF	Citations
19	Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction. JHEP Reports, 2021, 3, 100218.	2.6	26
20	A Dynamic Aspartateâ€toâ€Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease. Hepatology Communications, 2021, 5, 1021-1035.	2.0	23
21	Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls. Clinical Gastroenterology and Hepatology, 2020, 18, 1592-1599.e8.	2.4	21
22	Automated quantification of steatosis: agreement with stereological point counting. Diagnostic Pathology, 2017, 12, 80.	0.9	15
23	Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography. Scandinavian Journal of Gastroenterology, 2020, 55, 848-859.	0.6	15
24	Low hepatic manganese concentrations in patients with hepatic steatosis â€“ A cohort study of copper, iron and manganese in liver biopsies. Journal of Trace Elements in Medicine and Biology, 2021, 67, 126772.	1.5	15
25	Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2016, 51, 1126-1132.	0.6	13
26	Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. Hormones, 2022, 21, 349-368.	0.9	12
27	Modifiers of Liver-Related Manifestation in the Course of NAFLD. Current Pharmaceutical Design, 2020, 26, 1062-1078.	0.9	8
28	Repeated measurements of nonâ€invasive fibrosis tests to monitor the progression of nonâ€alcoholic fatty liver disease: A longâ€term followâ€up study. Liver International, 2022, 42, 1545-1556.	1.9	6
29	Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. BMC Gastroenterology, 2021, 21, 180.	0.8	5
30	Hepatic patatinâ€like phospholipase domainâ€containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans. Hepatology Communications, 2022, 6, 2689-2701.	2.0	5
31	Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. Scandinavian Journal of Gastroenterology, 2021, 56, 437-442.	0.6	4
32	Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. Scandinavian Journal of Gastroenterology, 2022, 57, 60-69.	0.6	3
33	Reply. Hepatology, 2016, 64, 310-311.	3.6	0